Urvish Patel

Dr. Urvish Patel

Icahn School of Medicine at Mount Sinai, New York, NY, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2019 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Urvish PatelUrvish Patel
Urvish Patel
AAArsalan Anwar
Arsalan Anwar
SSSidra Saleem
Sidra Saleem
PMPreeti Malik
Preeti Malik
BRBakhtiar Rasul
Bakhtiar Rasul
KAKogulavadanan Arumaithurai
Kogulavadanan Arumaithurai

20 July 2022 in Cureus
Verified
Journal Article
Open access
AJAditya Joshi
Aditya Joshi
KPKaran Patel
Karan Patel
AMAleem Mohamed
Aleem Mohamed
SOSolomon Oak
Solomon Oak
MZMichelle H. Zhang
Michelle H. Zhang
Urvish PatelUrvish Patel
Urvish Patel
In carpal tunnel syndrome (CTS), the median nerve is compressed at the level of the carpal tunnel in the wrist. This entrapment manifests as unpleasant symptoms, such as burning, tingling, or numbness in the palm that extends to the fingers. As the disease progresses, afflicted individuals also report decreased grip strength accompanied by hand weakness and restricted movement. The first half of this review elaborates on CTS pathology by providing readers with a comprehensive understanding of the etiology, relevant anatomy, and disease mechanism. CTS is considered the most common entrapment neuropathy, affecting around 3-6% of the adult population. Further, CTS prevalence has seen a dramatic increase in the last few decades paralleling the growth of everyday technology usage. Despite how common it is to have CTS, it can be quite challenging for physicians to make a definite diagnosis due to differentials that present with overlapping symptoms. Even more difficult can be deciding on a course of treatment that is the most effective and considerate of patient needs. Thus arises the need for clear clinical direction, and hence we end with a discussion around such guidelines that serve as a starting point toward effective diagnoses and patient treatment.

8 April 2019 in Cureus
Verified
Journal Article
Open access
PDF file
Urvish PatelUrvish Patel
Urvish Patel
PMPreeti Malik
Preeti Malik
MDMatthew DeMasi
Matthew DeMasi
ALAbhishek Lunagariya
Abhishek Lunagariya
VJVishal B. Jani
Vishal B. Jani
In rural and underserved areas, there are restrictions in healthcare due to the lack of availability of neurologists; patients have to travel long distances to receive the required care. Considering the fact that neurological conditions have large mortality and disability rates, there is a need for innovative services like tele-neurology. It is an important tool in improving the health and quality of life by using different ways of communication between neurologists and patients, or neurologists and other providers. We examine the current types of facilities available in tele-neurology, as well as outcomes, barriers, limitations, legal litigations, and the multidisciplinary nature based on prior studies. We have also suggested recommendations for the future of tele-neurology including effective-accessibility and inexpensive-utilization in developing countries. There are various tele-health programs created by The Veterans Health Administration including a clinical video tele-health (CVT) system. This system allows direct patient care of veterans by neurologists. The University of South Carolina implemented a web-based tele-stroke program in which acute ischemic stroke patients were treated in the Emergency Department (ED) of rural hospitals by neurologists, after consulting with rural ED physicians. With growing technology and popularity of tele-neurology, there are now international collaborative efforts in tele-medicine that are looking to be adapted to tele-neurology. Thus, tele-neurology can provide quality neurological care with patient satisfaction, as well as time and cost savings. The tele-stroke group established by TRUST-tPA trial (Therapeutic Trial Evaluating Efficacy of Telemedicine (TELESTROKE) of Patients With Acute Stroke) has 10 community hospital-emergency rooms that were connected to a stroke center. It was found that tele-stroke is appropriate in places where there is no way for a patient to access a stroke unit within a 4.5-hour time window. Like other tele-neurology subtypes, tele-epilepsy and pediatric tele-neurology also offer more follow-up care to people of remote areas which have limited access. There are other subtypes like mental health, chronic neurological care, and hospitalist which are very effective in improving outcome and quality of life of people living in remote areas. Tele-neurology has effectively reduced travel costs and times; there is high patient satisfaction and reduced disparity for general and specialized neurological care. But there are certain limitations like large equipment costs, certain bandwidth requirement, and trained staff to use the equipment. Transmission of patient information using public internet raises the concern of legality. There should be sufficient encryption to satisfy the Health Insurance Portability and Accountability Act (HIPAA) requirements to ensure patient confidentiality and safety of personal data. The adaptation of tele-neurology is a powerful and innovative way to enhance healthcare in areas with a shortage of specialists. Implementation of this tool is limited due to cost burden, lack of expertise to implement necessary technology, legal litigations, and suitable financial and professional incentives for the users. This review focuses on the trajectory of utilization and the issues to be addressed in order to provide the full benefits of tele-neurology to undeserved communities in the future.

23 April 2021 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
JMJagmeet Singh, MD
Jagmeet Singh, MD
PMPreeti Malik
Preeti Malik
NPNidhi Patel
Nidhi Patel
SPSuveenkrishna Pothuru
Suveenkrishna Pothuru
AIAvantika Israni
Avantika Israni
AKAsim Kichloo
Asim Kichloo

1 May 2020 in The Neurologist
Verified
Journal Article
Closed access
Urvish PatelUrvish Patel
Urvish Patel
NKNishanth Kodumuri
Nishanth Kodumuri
MDMihir Md Dave
Mihir Md Dave
ALAnusha Lekshminarayanan
Anusha Lekshminarayanan
NKNashmia Khan
Nashmia Khan
VJVishal Jani
Vishal Jani
Introduction: Pneumonia is the most common complication after stroke, but our knowledge on risk factors and predictors of stroke-associated pneumonia (SAP) is limited. We sought to evaluate the predictors and outcomes of SAP among acute ischemic stroke (AIS) hospitalizations.Methods: This is a cross-sectional study of the Nationwide Inpatient Sample database from the year 2003 to 2014. We identified adult hospitalizations with AIS using International Classification of Diseases, ninth revision, clinical modification (ICD-9-CM) codes. The SAP was identified by the presence of a secondary diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia. Multivariable survey logistic regression models were utilized to evaluate the predictors of SAP.Results: Overall, 4,224,924 AIS hospitalizations were identified, of which 149,169 (3.53%) had SAP. The prevalence of SAP decreased from 3.72% in 2003 to 3.17% in 2014 (P<0.0001). Mortality [17.12% vs. 4.77%; adjusted odds ratio (aOR): 1.71;P<0.0001] and morbidity (22.53% vs. 3.28%; aOR: 1.86;P<0.0001) were markedly elevated in SAP group compare to non-SAP group. The significant risk factors of pneumonia among AIS hospitalization were nasogastric tube (aOR: 1.21;P=0.0179), noninvasive mechanical ventilation (aOR: 1.65;P<0.0001), invasive mechanical ventilation (aOR: 4.09;P<0.0001), length of stay between 1 to 2 weeks (aOR: 1.99;P2 weeks (aOR: 3.90;P<0.0001), hemorrhagic conversion (aOR: 1.17;P=0.0002), and epilepsy (aOR: 1.09;P=0.0009). Other concurrent comorbidities which increased the risk of SAP among AIS patients were acquired immune deficiency syndrome (aOR: 1.88;P<0.0001), alcohol abuse (aOR: 1.60;P=0.0006), deficiency anemia (aOR: 1.26;P<0.0001), heart failure (aOR: 1.62;P<0.0001), pulmonary disease (aOR: 1.73;P<0.0001), diabetes (aOR: 1.29;P=0.0288), electrolyte disorders (aOR: 1.50;P<0.0001), paralysis (aOR: 1.22;P<0.0001), pulmonary circulation disorders (aOR: 1.22;P<0.0001), renal failure (aOR: 1.12;P<0.0001), coagulopathy (aOR: 1.13;P=0.0006), and weight loss (aOR: 1.39;P<0.0001).Conclusion: Our data underline the considerable epidemiological and prognostic impact of SAP in patients with AIS leading to higher mortality, morbidity, length of stay, and hospital cost despite advancements in care.

26 June 2019 in Cureus
Verified
Journal Article
Open access
PDF file
AAArsalan Anwar
Arsalan Anwar
SSSidra Saleem
Sidra Saleem
Urvish PatelUrvish Patel
Urvish Patel
KAKogulavadanan Arumaithurai
Kogulavadanan Arumaithurai
PMPreeti Malik
Preeti Malik
Dravet syndrome (DS), also known as severe myoclonic epilepsy of infancy (SMEI), is one of the rare early childhood intractable epileptic encephalopathies associated with pleomorphic seizure activity, cognitive decline, motor, and behavioral abnormalities. The convulsive seizure is the most common type seen in DS. After the first episode of seizure-like activity, behavioral disorders and cognitive decline are progressive and long-lasting. The most common etiology identified in patients with DS is a de-novo genetic mutation alpha-1 subunit of voltage-gated calcium channel gene (SCN1A). DS is diagnosed clinically and if unclear, genetic testing is recommended. DS treatment options include anti-epileptic drugs and cannabinoids; ketogenic diet therapy and surgical options such as the deep brain and vagal nerve stimulation. Due to drug-refractory epilepsy in DS, many more therapies are being investigated to increase the longevity of patients.